Entry - #620157 - INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 70; MRD70 - OMIM
# 620157

INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 70; MRD70


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
3p21.31 Intellectual developmental disorder, autosomal dominant 70 620157 AD 3 SETD2 612778
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEAD & NECK
Head
- Low-normal head circumference
- Brachycephaly
Face
- Dysmorphic facial features, variable (in some patients)
- Hypotonic facies
- Malar flattening
- Retrognathia
Eyes
- Upslanting palpebral fissures
- Straight eyebrows
- Myopia
- Strabismus
Mouth
- High-arched palate
Teeth
- Crowded teeth
SKELETAL
Hands
- Fifth finger clinodactyly
- Camptodactyly
NEUROLOGIC
Central Nervous System
- Global developmental delay
- Mildly delayed walking
- Impaired fine motor skills
- Impaired intellectual development, moderate
- Learning difficulties
- Speech delay
- Impaired speech
- Hypotonia
Behavioral Psychiatric Manifestations
- Behavioral abnormalities
PRENATAL MANIFESTATIONS
Amniotic Fluid
- Polyhydramnios (1 patient)
MISCELLANEOUS
- Onset in infancy
- De novo mutation
- Three unrelated patients have been reported (last curated December 2022)
MOLECULAR BASIS
- Caused by mutation in the SET domain-containing protein 2 gene (SETD2, 612778.0006)
Intellectual developmental disorder, autosomal dominant - PS156200 - 66 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.11 Coffin-Siris syndrome 2 AD 3 614607 ARID1A 603024
1q21.3 White-Sutton syndrome AD 3 616364 POGZ 614787
1q21.3 GAND syndrome AD 3 615074 GATAD2B 614998
1q22 Intellectual developmental disorder, autosomal dominant 52 AD 3 617796 ASH1L 607999
1q44 Intellectual developmental disorder, autosomal dominant 22 AD 3 612337 ZBTB18 608433
2p25.3 Intellectual developmental disorder, autosomal dominant 39 AD 3 616521 MYT1L 613084
2q11.2 ?Intellectual developmental disorder, autosomal dominant 69 AD 3 617863 LMAN2L 609552
2q23.1 Intellectual developmental disorder, autosomal dominant 1 AD 3 156200 MBD5 611472
3p25.3 Intellectual developmental disorder, autosomal dominant 23 AD 3 615761 SETD5 615743
3p21.31 Intellectual developmental disorder, autosomal dominant 70 AD 3 620157 SETD2 612778
3q22.3 Intellectual developmental disorder, autosomal dominant 47 AD 3 617635 STAG1 604358
3q26.32 Intellectual developmental disorder, autosomal dominant 41 AD 3 616944 TBL1XR1 608628
3q27.1 Intellectual developmental disorder 60 with seizures AD 3 618587 AP2M1 601024
4q31.1 Intellectual developmental disorder, autosomal dominant 50, with behavioral abnormalities AD 3 617787 NAA15 608000
5p15.2 Intellectual developmental disorder, autosomal dominant 63, with macrocephaly AD 3 618825 TRIO 601893
5p15.2 Intellectual developmental disorder, autosomal dominant 44, with microcephaly AD 3 617061 TRIO 601893
5q13.3 Intellectual developmental disorder, autosomal dominant 34 AD 3 616351 COL4A3BP 604677
5q32 Intellectual developmental disorder, autosomal dominant 53 AD 3 617798 CAMK2A 114078
5q33.2 Intellectual developmental disorder, autosomal dominant 67 AD 3 619927 GRIA1 138248
6p21.32 Intellectual developmental disorder, autosomal dominant 5 AD 3 612621 SYNGAP1 603384
6q13 Intellectual developmental disorder, autosomal dominant 46 AD 3 617601 KCNQ5 607357
6q14.3 Intellectual developmental disorder, autosomal dominant 64 AD 3 619188 ZNF292 616213
6q22.1 Intellectual developmental disorder, autosomal dominant 55, with seizures AD 3 617831 NUS1 610463
6q24.2 Intellectual developmental disorder, autosomal dominant 43 AD 3 616977 HIVEP2 143054
6q25.3 Coffin-Siris syndrome 1 AD 3 135900 ARID1B 614556
7p22.1 Intellectual developmental disorder, autosomal dominant 48 AD 3 617751 RAC1 602048
7p13 Intellectual developmental disorder, autosomal dominant 54 AD 3 617799 CAMK2B 607707
7q11.22 Intellectual developmental disorder, autosomal dominant 26 AD 3 615834 KIAA0442 607270
7q36.2 Intellectual developmental disorder, autosomal dominant 33 AD 3 616311 DPP6 126141
9p24 Intellectual developmental disorder, autosomal dominant 2 AD 4 614113 MRD2 614113
9q34.11 Intellectual developmental disorder, autosomal dominant 58 AD 3 618106 SET 600960
9q34.3 Kleefstra syndrome 1 AD 3 610253 EHMT1 607001
10p15.3 Intellectual developmental disorder, autosomal dominant 30 AD 3 616083 ZMYND11 608668
10q22.2 Intellectual developmental disorder, autosomal dominant 59 AD 3 618522 CAMK2G 602123
11p15.5 Vulto-van Silfout-de Vries syndrome AD 3 615828 DEAF1 602635
11q13.1 Coffin-Siris syndrome 7 AD 3 618027 DPF2 601671
11q13.1-q13.2 Schuurs-Hoeijmakers syndrome AD 3 615009 PACS1 607492
11q13.2 Intellectual developmental disorder, autosomal dominant 51 AD 3 617788 KMT5B 610881
11q24.2 Intellectual developmental disorder, autosomal dominant 4 AD 2 612581 MRD4 612581
12p13.1 Intellectual developmental disorder, autosomal dominant 6, with or without seizures AD 3 613970 GRIN2B 138252
12q12 Coffin-Siris syndrome 6 AD 3 617808 ARID2 609539
12q13.12 Intellectual developmental disorder, autosomal dominant, FRA12A type AD 3 136630 DIP2B 611379
12q13.2 Coffin-Siris syndrome 8 AD 3 618362 SMARCC2 601734
12q21.33 Intellectual developmental disorder, autosomal dominant 66 AD 3 619910 ATP2B1 108731
14q11.2 Intellectual developmental disorder, autosomal dominant 74 AD 3 620688 HNRNPC 164020
15q21.3 Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities AD 3 620330 RFX7 612660
16p13.3 Intellectual developmental disorder, autosomal dominant 72 AD 3 620439 SRRM2 606032
16q22.1 Intellectual developmental disorder, autosomal dominant 21 AD 3 615502 CTCF 604167
16q24.3 Intellectual developmental disorder, autosomal dominant 3 AD 3 612580 CDH15 114019
17p13.1 Intellectual developmental disorder, autosomal dominant 62 AD 3 618793 DLG4 602887
17q21.2 Coffin-Siris syndrome 5 AD 3 616938 SMARCE1 603111
17q21.31 Koolen-De Vries syndrome AD 3 610443 KANSL1 612452
17q23.1 Intellectual developmental disorder, autosomal dominant 56 AD 3 617854 CLTC 118955
17q23.2 Intellectual developmental disorder, autosomal dominant 61 AD 3 618009 MED13 603808
17q23.2 Intellectual developmental disorder, autosomal dominant 57 AD 3 618050 TLK2 608439
18q12.3 Intellectual developmental disorder, autosomal dominant 29 AD 3 616078 SETBP1 611060
19p13.3 Intellectual developmental disorder, autosomal dominant 65 AD 3 619320 KDM4B 609765
19p13.2 Coffin-Siris syndrome 4 AD 3 614609 SMARCA4 603254
19q13.12 Intellectual developmental disorder, autosomal dominant 68 AD 3 619934 KMT2B 606834
19q13.2 Intellectual developmental disorder, autosomal dominant 45 AD 3 617600 CIC 612082
20q11.23 ?Intellectual developmental disorder, autosomal dominant 11 AD 3 614257 EPB41L1 602879
20q13.33 Intellectual developmental disorder, autosomal dominant 73 AD 3 620450 TAF4 601796
20q13.33 Intellectual developmental disorder, autosomal dominant 38 AD 3 616393 EEF1A2 602959
21q22.13 Intellectual developmental disorder, autosomal dominant 7 AD 3 614104 DYRK1A 600855
22q11.23 Coffin-Siris syndrome 3 AD 3 614608 SMARCB1 601607
22q12.3 ?Intellectual developmental disorder, autosomal dominant 10 AD 3 614256 CACNG2 602911

TEXT

A number sign (#) is used with this entry because of evidence that autosomal dominant intellectual developmental disorder-70 (MRD70) is caused by a specific heterozygous missense mutation (R1740Q) in the SETD2 gene (612778) on chromosome 3p21.


Description

Autosomal dominant intellectual developmental disorder-70 (MRD70) is characterized by mild global developmental delay, moderately impaired intellectual disability with speech difficulties, and behavioral abnormalities. More variable findings may include hypotonia and dysmorphic features (Rabin et al., 2020)


Clinical Features

Rabin et al. (2020) reported 3 unrelated patients (group 2) with mild to moderately impaired intellectual development associated with a specific de novo heterozygous mutation in the SETD2 gene (R1740Q; 612778.0006). The patients were ascertained through collaborative efforts after the mutation was identified, and the phenotype was delineated retrospectively. They had mild global developmental delay and speech delay, but all achieved independent walking. Patient 1 was 15-year-old boy who attended a special school, showed behavioral abnormalities, and had a developmental level of a 6-year-old. Dysmorphic features included upslanting palpebral fissures, upslanting straight-lined eyebrows, brachycephaly, fifth finger clinodactyly, and camptodactyly. Patient 2 was a 4.5-year-old boy with poor speech, hypotonia, strabismus, and joint hyperlaxity. Brain imaging was normal. The pregnancy had been complicated by polyhydramnios. Patient 3 was an 8-year-old girl with IQ levels between 67 and 76 and behavioral abnormalities. Notable facial features included high-arched palate, crowded teeth, retrognathia, myopia, malar flattening, and broad eyebrows. She also had hypotonia.


Inheritance

The heterozygous mutations in the SETD2 gene that were identified in patients with MRD70 by Rabin et al. (2020) occurred de novo.


Molecular Genetics

In 3 unrelated patients (group 2) with MRD70, Rabin et al. (2020) identified a de novo heterozygous missense mutation in the SETD2 gene (R1740Q; 612778.0006). The mutation, which was found thorough clinical genetics services, was not present in the gnomAD database. The patients were ascertained through collaborative efforts, and the phenotype determined retrospectively. Functional studies of the variant and studies of patient cells were not performed. The patients had developmental delay with moderately impaired intellectual development, low-normal head circumference, variable and mild dysmorphic features, and absence of additional congenital anomalies or systemic involvement. The phenotype was considered to be different from that of patients with other mutations in the SETD2 gene, including those with a different mutation at the same codon (see R1740W, 612778.0005).


REFERENCES

  1. Rabin, R., Radmanesh, A., Glass, I. A., Dobyns, W. B., Aldinger, K. A., Shieh, J. T., Romoser, S., Bombei, H., Dowsett, L., Trapane, P., Bernat, J. A., Baker, J., and 29 others. Genotype-phenotype correlation at codon 1740 of SETD2. Am. J. Med. Genet. 182A: 2037-2048, 2020. [PubMed: 32710489, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 12/12/2022
alopez : 12/13/2022
ckniffin : 12/12/2022

# 620157

INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 70; MRD70


ORPHA: 178469, 597743;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
3p21.31 Intellectual developmental disorder, autosomal dominant 70 620157 Autosomal dominant 3 SETD2 612778

TEXT

A number sign (#) is used with this entry because of evidence that autosomal dominant intellectual developmental disorder-70 (MRD70) is caused by a specific heterozygous missense mutation (R1740Q) in the SETD2 gene (612778) on chromosome 3p21.


Description

Autosomal dominant intellectual developmental disorder-70 (MRD70) is characterized by mild global developmental delay, moderately impaired intellectual disability with speech difficulties, and behavioral abnormalities. More variable findings may include hypotonia and dysmorphic features (Rabin et al., 2020)


Clinical Features

Rabin et al. (2020) reported 3 unrelated patients (group 2) with mild to moderately impaired intellectual development associated with a specific de novo heterozygous mutation in the SETD2 gene (R1740Q; 612778.0006). The patients were ascertained through collaborative efforts after the mutation was identified, and the phenotype was delineated retrospectively. They had mild global developmental delay and speech delay, but all achieved independent walking. Patient 1 was 15-year-old boy who attended a special school, showed behavioral abnormalities, and had a developmental level of a 6-year-old. Dysmorphic features included upslanting palpebral fissures, upslanting straight-lined eyebrows, brachycephaly, fifth finger clinodactyly, and camptodactyly. Patient 2 was a 4.5-year-old boy with poor speech, hypotonia, strabismus, and joint hyperlaxity. Brain imaging was normal. The pregnancy had been complicated by polyhydramnios. Patient 3 was an 8-year-old girl with IQ levels between 67 and 76 and behavioral abnormalities. Notable facial features included high-arched palate, crowded teeth, retrognathia, myopia, malar flattening, and broad eyebrows. She also had hypotonia.


Inheritance

The heterozygous mutations in the SETD2 gene that were identified in patients with MRD70 by Rabin et al. (2020) occurred de novo.


Molecular Genetics

In 3 unrelated patients (group 2) with MRD70, Rabin et al. (2020) identified a de novo heterozygous missense mutation in the SETD2 gene (R1740Q; 612778.0006). The mutation, which was found thorough clinical genetics services, was not present in the gnomAD database. The patients were ascertained through collaborative efforts, and the phenotype determined retrospectively. Functional studies of the variant and studies of patient cells were not performed. The patients had developmental delay with moderately impaired intellectual development, low-normal head circumference, variable and mild dysmorphic features, and absence of additional congenital anomalies or systemic involvement. The phenotype was considered to be different from that of patients with other mutations in the SETD2 gene, including those with a different mutation at the same codon (see R1740W, 612778.0005).


REFERENCES

  1. Rabin, R., Radmanesh, A., Glass, I. A., Dobyns, W. B., Aldinger, K. A., Shieh, J. T., Romoser, S., Bombei, H., Dowsett, L., Trapane, P., Bernat, J. A., Baker, J., and 29 others. Genotype-phenotype correlation at codon 1740 of SETD2. Am. J. Med. Genet. 182A: 2037-2048, 2020. [PubMed: 32710489] [Full Text: https://doi.org/10.1002/ajmg.a.61724]


Creation Date:
Cassandra L. Kniffin : 12/12/2022

Edit History:
alopez : 12/13/2022
ckniffin : 12/12/2022